| Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade W Abida, ML Cheng, J Armenia, S Middha, KA Autio, HA Vargas, ... JAMA oncology 5 (4), 471-478, 2019 | 545 | 2019 |
| High-risk prostate cancer—classification and therapy AJ Chang, KA Autio, M Roach III, HI Scher Nature reviews Clinical oncology 11 (6), 308-323, 2014 | 455 | 2014 |
| Safety, antitumor activity, and immune activation of pegylated recombinant human interleukin-10 (AM0010) in patients with advanced solid tumors A Naing, KP Papadopoulos, KA Autio, PA Ott, MR Patel, DJ Wong, ... Journal of Clinical Oncology 34 (29), 3562, 2016 | 232 | 2016 |
| PEGylated IL-10 (Pegilodecakin) induces systemic immune activation, CD8+ T cell invigoration and polyclonal T cell expansion in cancer patients A Naing, JR Infante, KP Papadopoulos, IH Chan, C Shen, NP Ratti, ... Cancer Cell 34 (5), 775-791. e3, 2018 | 219 | 2018 |
| Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of … E Basch, K Autio, CJ Ryan, P Mulders, N Shore, T Kheoh, K Fizazi, ... The lancet oncology 14 (12), 1193-1199, 2013 | 204 | 2013 |
| Safety and efficacy of BIND-014, a docetaxel nanoparticle targeting prostate-specific membrane antigen for patients with metastatic castration-resistant prostate cancer: a … KA Autio, R Dreicer, J Anderson, JA Garcia, A Alva, LL Hart, MI Milowsky, ... JAMA oncology 4 (10), 1344-1351, 2018 | 198 | 2018 |
| Probody therapeutics: an emerging class of therapies designed to enhance on-target effects with reduced off-tumor toxicity for use in immuno-oncology KA Autio, V Boni, RW Humphrey, A Naing Clinical Cancer Research 26 (5), 984-989, 2020 | 112 | 2020 |
| Targeting the androgen receptor in prostate and breast cancer: several new agents in development T Proverbs-Singh, JL Feldman, MJ Morris, KA Autio, TA Traina Endocrine-related cancer 22 (3), R87-R106, 2015 | 107 | 2015 |
| Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial A Naing, DJ Wong, JR Infante, WM Korn, R Aljumaily, KP Papadopoulos, ... The Lancet Oncology 20 (11), 1544-1555, 2019 | 94 | 2019 |
| Low bone mineral density in adolescents with β‐thalassemia MG Vogiatzi, KA Autio, JE Mait, R Schneider, M Lesser, PJ Giardina Annals of the New York Academy of Sciences 1054 (1), 462-466, 2005 | 78 | 2005 |
| Response of albumin synthesis to oral nutrients in young and elderly subjects G Caso, J Feiner, I Mileva, LJ Bryan, P Kelly, K Autio, MC Gelato, ... The American journal of clinical nutrition 85 (2), 446-451, 2007 | 72 | 2007 |
| Low bone mass in prepubertal children with thalassemia major: insights into the pathogenesis of low bone mass in thalassemia MG Vogiatzi,, KA Autio,, R Schneider, PJ Giardina Journal of Pediatric Endocrinology and Metabolism 17 (10), 1415-1422, 2004 | 52 | 2004 |
| Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohort E Basch, KA Autio, MR Smith, AV Bennett, AL Weitzman, C Scheffold, ... European urology 67 (2), 310-318, 2015 | 48 | 2015 |
| Therapeutic strategies for bone metastases and their clinical sequelae in prostate cancer KA Autio, HI Scher, MJ Morris Current treatment options in oncology 13, 174-188, 2012 | 46 | 2012 |
| 609O Results from a phase I study of AMG 160, a half-life extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTE®) immune therapy for metastatic castration-resistant … B Tran, L Horvath, T Dorff, M Rettig, MP Lolkema, JP Machiels, S Rottey, ... Annals of Oncology 31, S507, 2020 | 44 | 2020 |
| Pegylated interleukin-10: clinical development of an immunoregulatory cytokine for use in cancer therapeutics K Autio, M Oft Current Oncology Reports 21, 1-7, 2019 | 38 | 2019 |
| Immunomodulatory activity of a colony-stimulating factor-1 receptor inhibitor in patients with advanced refractory breast or prostate cancer: a phase I study KA Autio, CA Klebanoff, D Schaer, JSW Kauh, SF Slovin, M Adamow, ... Clinical Cancer Research 26 (21), 5609-5620, 2020 | 37 | 2020 |
| Prevalence of pain and analgesic use in men with metastatic prostate cancer using a patient-reported outcome measure KA Autio, AV Bennett, X Jia, M Fruscione, TM Beer, DJ George, ... Journal of oncology practice 9 (5), 223-229, 2013 | 36 | 2013 |
| Monitoring the clinical outcomes in advanced prostate cancer: what imaging modalities and other markers are reliable? MJ Morris, KA Autio, EM Basch, DC Danila, S Larson, HI Scher Seminars in oncology 40 (3), 375-392, 2013 | 36 | 2013 |
| Phase I study of MK-4166, an anti-human glucocorticoid-induced TNF receptor antibody, alone or with pembrolizumab in advanced solid tumors KP Papadopoulos, K Autio, T Golan, K Dobrenkov, E Chartash, Q Chen, ... Clinical Cancer Research 27 (7), 1904-1911, 2021 | 35 | 2021 |
